Acxel Boxin Tech Secures Nearly RMB 100 Million Series A Funding Led by Luxin Venture Capital to Advance Digital Microfluidics Platform

VCBeat has learned that recently,Foshan Auso Bo Xin Technology Co., Ltd. (hereinafter referred to as "Auso Tech")Announced the completion of a nearly RMB 100 million Series A financing round. This round was led by Luxin Venture Capital, with existing shareholders Qiming Venture Partners, Linear Capital, and Cowin Capital continuing to increase their investments. WinX Capital served as the exclusive financial advisor for three consecutive rounds.Following this round of financing, Ausu Technology will further accelerate the commercialization of its offerings in the field of single-cell proteomics, providing differentiated products and services to address unmet needs in laboratory sample pre-processing, functional discovery, and validation. The company strives to bring advanced life science instruments made in China to the global market.

Ausoo Technology, established in 2021, boasts a globally leading active digital microfluidic droplet manipulation platform. Within just over two years, the company has successfully secured four consecutive rounds of financing, with its shareholders comprising numerous top-tier venture capital firms and renowned industrial investors.

The company’s first commercialized product, Boxmini™ SCP, is the world’s first fully automated microfluidic lab-on-a-chipSingle-Cell Proteomics Sample Preparation Tools, efficiently assisting users in achieving high-throughput, rapid, and precise control of micro-volume samples, enabling one-stop completion of complex single-cell protein sample preparation, and compatible with both label-free and TMT labeling workflows; the product has garnered significant market attention since its launch.

For this financing round,Dr. Ma Hanbin, Founder and CEO of Aosu Technologystated: “By introducing consumer electronics semiconductor technology into the life sciences sector, the Aosue team has achieved foundational progress from zero to one. Specifically, in the application scenario of sample preparation for single-cell proteomics, we have gained recognition from leading principal investigators (PIs) both domestically and internationally through our capabilities in precise nanoliter-scale sample manipulation using active digital microfluidic microchips and full-process integration, yielding experimental results that advance the entire field. In other areas such as single-cell multi-omics, microbiology, and synthetic biology, Aosue will collaborate with various downstream partners to accelerate new product development and commercialization. With the support of both existing and new shareholders, we will leverage our technological advantages to rapidly expand into domestic and international markets. Using single-cell proteomics products as a breakthrough point, we aim to build a biochip ecosystem based on semiconductor technology through an open digital microfluidic shared platform, thereby accelerating the entry of life science laboratories and medical testing automation into the consumer electronics era.”

Lead investor in this round,Qiu Fang, Deputy General Manager of Luxin Venture CapitalLuxin Venture Capital stated: “As a state-controlled professional venture capital firm, Luxin Venture Capital has consistently prioritized supporting the application and commercialization of achievements from China’s independent research platforms and scientific instruments through venture investment, thereby advancing the nation’s high-level technological self-reliance and strength. Ausu Technology possesses core foundational technologies in active digital microfluidics, with the potential to propel laboratory automation into a new era and establish novel research platforms. The company’s single-cell proteomics product provides advanced tools for cutting-edge research such as single-cell multi-omics, garnering significant attention from downstream clients, including portfolio companies of Luxin Venture Capital. This demonstrates the high level of self-reliance and strength achieved by domestically produced scientific instruments, heralding a new phase of development. Luxin Venture Capital will support Ausu Technology in its critical efforts to accelerate the localization of scientific instruments and equipment.”

Chen Kan, Partner at Qiming Venture Partners“Qiming Venture Partners, as the lead investor in the previous round, has participated in two consecutive rounds of capital increase for Ausu Technology. Leveraging its strong R&D capabilities and excellent execution, the company has rapidly launched a flagship product in the single-cell field, targeting a blue-ocean market. We are confident in the company’s future and will continue to support its commercialization efforts in overseas markets, looking forward to seeing Ausu Technology bring advanced scientific instruments of ‘Intelligent Manufacturing in China’ to the global stage.”

Linear Capital Managing Director Zheng CanLinear Capital, as the lead investor in the angel round, firmly believes that investment hinges on identifying the right people. We have witnessed firsthand Dr. Ma Hanbin’s transformation from a researcher into a modern entrepreneur. We are deeply impressed by his character, scientific acumen, forward-looking vision, and entrepreneurial spirit. Under his leadership, the company launched a groundbreaking single-cell proteomics solution, further energizing global research in the field of proteomics. In this round, we have increased our stake to propel Ausu Technology toward becoming a benchmark enterprise in advanced scientific instruments.

Xi Yanbin, Partner at Cowin Capital Beijing Healthcare Fundstated: “We have always believed that Aosu Technology’s digital microfluidic chip system is poised to become a key carrier for next-generation life science microreactors, continuously providing innovative solutions for scientific research, the pharmaceutical industry, and more. The company’s single-cell proteomics product has advanced proteomics research to a practically feasible single-cell resolution, enabling customers to transcend tool limitations and validate existing knowledge while exploring the unknown from entirely new perspectives. We have continued to increase our stake in this funding round, looking forward to seeing Aosu Technology bring its advanced technologies to full fruition in practical applications.”

Zou Guowen, Founding Partner of WinX Capital“WinX Capital is honored to have served as the exclusive financial advisor for Ausu Technology’s financing rounds for three consecutive times, witnessing Ausu’s journey from a startup through rapid growth to commercialization. As a leading enterprise in the digital microfluidics industry, Ausu has successfully navigated market cycles and secured four rounds of financing within less than three years, fully demonstrating strong recognition from the investment community. We look forward to Ausu’s further expansion into downstream sectors, aiming to become a world-leading life sciences tools company.”

Luxin Venture Capital Group Co., Ltd. (Stock Code: 600783.SH), controlled by Shandong Luxin Investment Holding Group Co., Ltd., is the largest professional venture capital firm in Shandong Province and one of the most influential in China. It is the first venture capital institution listed on China’s domestic capital market. Over the past two decades, the company has managed and operated more than 40 funds with a total scale of approximately RMB 20 billion. Its investments span across healthcare, military-civilian integration, advanced manufacturing, electronic information, new energy, and new materials. The portfolio includes over 40 companies listed both domestically and internationally. In the healthcare sector, it has invested in a number of outstanding enterprises such as 3D Medicines, Silicon-Based Bionics, Zhongke New Life, Abclonal, Weimai Medical, Meidong Huicheng, Inscinstech, and RemeGen.

WinX Capital is a leading investment bank in China’s healthcare sector, with headquarters in Beijing and Shanghai, covering more than 3,000 active institutional investors and industrial groups. It has received numerous accolades, including “No. 1 Financial Advisor in the Healthcare Sector for 2022” by First New Voice, “Top 2 Best Financial Advisors in the Healthcare Sector for 2021–2022” by Qimingpian & Xinsheng Chuangfu, and “Top 5 Healthcare Financial Advisors of the Year” at the 2022–2023 Pengcheng Awards by VCBeat.